Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XQWYL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN115429893A ADC1
|
|||||
| Synonyms |
CN115429893A ADC1
Click to Show/Hide
|
|||||
| Organization |
Bio Thera Solutions Ltd
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
CN115429893A ADC1 Payload
|
Payload Info | ||||
| Linker Name |
CB07 linker
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth lnhibition value (TGl) |
105.8
|
%
|
Undisclosed | Undisclosed |
| Tumor Growth lnhibition value (TGl) |
105.8
|
%
|
Undisclosed | Undisclosed |
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 105.80% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
In the SKOV3 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | SKOV3 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 105.80% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
In the SKOV3 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | SKOV3 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 36 ng/mL | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
MDA-MB-453 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC1 for 120 h.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-453 cells | CVCL_0418 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 43 ng/mL | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
SK-BR-3 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC1 for 120 h.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 62 ng/mL | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
BT-474 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC1 for 120 h.
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 82 ng/mL | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
NCI-N87 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC1 for 120 h.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 10000 ng/mL | Negative HER2 expression (HER2-) | ||
| Method Description |
MDA-MB-468 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC1 for 120 h.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||